Enrollment on the AREN03B2 Renal Tumor Biology and Classification Study is required PRIOR to enrollment on the COG AREN0321
Age: <30 years old at the time of initial diagnosis
Newly diagnosed (Stages I-IV) of the following histological types are eligible
- Focal Anaplastic Wilms Tumor
- Diffuse Anaplastic Wilms Tumor
- Clear Cell Sarcoma of Kidney
- Malignant Rhabdoid Tumor (Renal or extra renal, excluding CNS tumors)
- Renal Cell Carcinoma (clear cell, papillary, renal medullary, oncocytoid, sarcomatoid, chromophobe, translocation, collecting duct, carcinoma associated with neuroblastoma, renal cell carcinoma unclassified)
Patients must begin protocol therapy on COG AREN0321 by Day 14 after surgery or biopsy unless medically contraindicated
Patients must not have received systemic chemotherapy or radiation therapy prior to treatment on this study UNLESS they were enrolled on the COG AREN0532 or AREN0533 studies and received pre-nephrectomy chemotherapy for what was originally presumed to be favorable histology Wilms tumor
Patients with pediatric RCC who previously received chemotherapy for another type of malignancy (not the RCC) or non-malignant condition may enroll on the study
Adequate liver and heart function